<DOC>
	<DOCNO>NCT02474082</DOCNO>
	<brief_summary>This randomize , control , multicenter , open-label study blind assessment efficacy subcutaneous secukinumab compare Fumaderm速 , 200 adult moderate severe plaque type psoriasis candidate systemic therapy . The study consist 2 period : screening period least one week four week , treatment period 24 week . During screen period eligibility patient confirm . Eligible patient randomize 1:1 treatment arm A B week 0 . Patients treatment arm A receive secukinumab administer week 0 , 1 , 2 , 3 , 4 , 8 , 12 , 16 20 follow assessment study endpoint week 24 . Patients treatment arm B receive daily dos Fumaderm速 p.o.. Safety efficacy measurement secukinumab Fumaderm速 perform throughout study week 24 .</brief_summary>
	<brief_title>Study Secukinumab Compared Fumaderm速 Adults With Moderate Severe Psoriasis .</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Men woman must least 18 year age time screen Chronic plaquetype psoriasis diagnose least 6 month randomization Patients moderate severe plaque psoriasis candidate systemic therapy define randomization : PASI score &gt; 10 Affected body surface area ( BSA ) &gt; 10 % DLQI &gt; 10 Inadequate response , intolerance contraindication topical psoriasis treatment document patient 's medical history report patient determine investigator screening . Exclusion Criteria ( abbreviate ) : Previous systemic treatment plaque psoriasis know contraindication systemic therapy baseline Ongoing use prohibit psoriasis nonpsoriasis treatment . Clinically important active infection infestation , chronic , recurrent latent infection infestation Patients severe liver diseases Patients severe gastrointestinal disease include limited ventricular duodenal ulcer Patients severe kidney disease serum creatinine 1 x ULN Patients known hematological disease lab abnormality Pregnancy , breast feeding , unwillingness/inability use appropriate measure contraception ( necessary )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>